Adenocarcinoma and Small Cell Lung Cancer (SCLC) Partial Transformation

These flashcards cover key terms and concepts related to the partial transformation of adenocarcinoma into small cell lung cancer, highlighting treatment responses, survival rates, and molecular features.

Partial Transformation

A subtype of lung cancer where only part of the tumor becomes small cell while the rest remains adenocarcinoma.

Osimertinib

A targeted therapy used to treat EGFR-mutated lung cancers, which remains beneficial even in partial transformation.

Platinum–Etoposide (PE) chemotherapy

A combination chemotherapy known for high response rates (70–90%) in treating mixed tumors.

Median Survival for Pure SCLC Transformation

6–12 months, compared to 18–36+ months for partial/mixed transformation.

p53 Wild-Type

Indicates a better molecular feature associated with incomplete neuroendocrine transformation and slower progression.

Synaptophysin

A marker that is positive in small cell components, supporting the diagnosis of small cell lung cancer.

CK Positive (Heterogeneous)

Consistent with a mixed phenotype of the tumor, indicating both adenocarcinoma and small cell features.

Immunotherapy Effectiveness

Generally not effective in transformed SCLC due to low PD-L1 expression and low tumor mutation burden (TMB).

Re-biopsy or Liquid Biopsy

Recommended post-chemotherapy to check if the tumor has reverted back to adenocarcinoma after treatment.

Molecular Profile

Indicates favorable biology and less aggressive behavior in patients with p53 wild type and mixed tumors.

Targeted Therapy in Lung Cancer

Treatment designed to specifically attack cancer cells based on their genetic profile, such as using Osimertinib for EGFR mutations.

Neuroendocrine Tumors

A type of tumor that arises from neuroendocrine cells, which have traits similar to both nerve cells and hormone-producing cells. They can occur in various organs, including the lungs.

Small Cell Lung Cancer (SCLC)

A fast-growing form of lung cancer that is characterized by small round cells and typically associated with cigarette smoking.

Adenocarcinoma

A type of lung cancer that originates in glandular tissues, often seen in non-smokers and linked to exposure to certain toxins.

Tumor Mutation Burden (TMB)

A measure of the total number of mutations in a tumor's DNA, which can influence the effectiveness of immunotherapy.

EGFR Mutation

A mutation in the epidermal growth factor receptor gene, often found in non-small cell lung cancers and targeted by specific therapies.

PD-L1 Expression

A protein that can be expressed on tumor cells and is a target for some immunotherapeutic agents; high levels are associated with better responses to checkpoints inhibitors.

Neuroendocrine Tumors

A type of tumor that arises from neuroendocrine cells, which have traits similar to both nerve cells and hormone-producing cells. They can occur in various organs, including the lungs.

Small Cell Lung Cancer (SCLC)

A fast-growing form of lung cancer that is characterized by small round cells and typically associated with cigarette smoking.

Adenocarcinoma

A type of lung cancer that originates in glandular tissues, often seen in non-smokers and linked to exposure to certain toxins.

Tumor Mutation Burden (TMB)

A measure of the total number of mutations in a tumor's DNA, which can influence the effectiveness of immunotherapy.

EGFR Mutation

A mutation in the epidermal growth factor receptor gene, often found in non-small cell lung cancers and targeted by specific therapies.

PD-L1 Expression

A protein that can be expressed on tumor cells and is a target for some immunotherapeutic agents; high levels are associated with better responses to checkpoints inhibitors.